Novacyt S.A. (Novacyt, the Company or the Group) Full Year 2022 Trading Update

Full year revenue and EBITDA in line with guidance Remain focused on post-COVID-19 growth strategy to become a leading global clinical diagnostics company in infectious diseases Regulatory News: Novacyt

Related Keywords

United Kingdom ,France ,Freddie Barnfield Duncan Monteith ,Foster Mitchell Alex Shaw ,Vadim Alexandre Rob Rees ,Matthew Johnson Charlie Bouverat ,James Mccarthy ,Durgetto Yannick Petit ,James Wakefield ,Sp Angel Corporate Finance ,Novacyt Group ,Consulting International ,European Union Withdrawal ,Regulatory Information Service ,Microgen Bioproducts ,Market Abuse Regulation ,European Union ,Non Executive Chairman ,Acting Chief Executive Officer ,Nominated Adviser ,Johnson Charlie Bouverat ,Corporate Finance ,Alexandre Rob Rees ,Corporate Broking ,Joint Broker ,Black Freddie Barnfield Duncan Monteith ,French Listing Sponsor ,Novacyt ,Company ,Group ,Bull ,Ear ,022 ,Trading ,Update ,